Intellia Therapeutics (NASDAQ:NTLA) just reported results for the first quarter of 2024.
- Intellia Therapeutics reported earnings per share of -$1.12. This was above the analyst estimate for EPS of -$1.38.
- The company reported revenue of $28.94 million.
- This was 151.61% better than the analyst estimate for revenue of $11.50 million.